High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarction Patients

References

• Riska Pertiwi GA, Ngurah Aryawangsa AA, Prabawa IPY, et al. Factors associated with visit-to-visit variability of blood pressure in hypertensive patients at a primary health care service, Tabanan, Bali, Indonesia. Fam Med Community Heal. 2018;6(4):191–199. doi:10.15212/FMCH.2018.0124
   Web of Science ®Google Scholar
• Tada H, Takamura M, Kawashiri M-A. Lipoprotein(a) as an old and new causal risk factor of atherosclerotic cardiovascular disease. J Atheroscler Thromb. 2019;26(7):583–591. doi:10.5551/jat.RV17034
   PubMed Web of Science ®Google Scholar
• Wiryadana KA, Supadmanaba IGP, Samatra IDPG. Progress and potential roles blood biomarkers of ischemic stroke in clinical setting. Indones J Biomed Sci. 2017;11(2):19–29. doi:10.15562/ijbs.v11i2.138
   Google Scholar
• Abu-Assi E, López-López A, González-Salvado V, et al. The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Española Cardiol. 2016;69(1):11–18. doi:10.1016/j.recesp.2015.06.016
   PubMed Web of Science ®Google Scholar
• Loria V, Leo M, Biasillo G, Dato I, Biasucci LM. Biomarkers in acute coronary syndrome. Biomark Insights. 2008;3:453–468. doi:10.4137/BMI.S588
   PubMedGoogle Scholar
• Gómez M, Valle V, Arós F, et al. Oxidized LDL, lipoprotein (a), and other emergent risk factors in acute myocardial infarction (FORTIAM study). Rev Española Cardiol. 2009;62(4):373–382. doi:10.1016/S0300-8932(09)70894-2
   PubMed Web of Science ®Google Scholar
• Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction. Circ J. 2006;70(2):156–162. doi:10.1253/circj.70.156
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Ballantyne CM, Barter PJ, et al. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol. 2018;3(2):164–168. doi:10.1001/jamacardio.2017.3833
   PubMed Web of Science ®Google Scholar
• Yan AT, Yan RT, Tan M, et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J. 2007;28(9):1072–1078. doi:10.1093/eurheartj/ehm004
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Morrow DA, Cannon CP, et al. Multimarker risk stratification in patients with acute myocardial infarction. J Am Heart Assoc. 2016;5(5):e002586.
   PubMed Web of Science ®Google Scholar
• Oemrawsingh RM, Akkerhuis KM, Umans VA, et al. Cohort profile of BIOMArCS: the BIOMarker study to identify the acute risk of a coronary syndrome-a prospective multicentre biomarker study conducted in the Netherlands. BMJ Open. 2016;6(12):e012929–e012929. doi:10.1136/bmjopen-2016-012929
   PubMed Web of Science ®Google Scholar
• McCormick SPA. Lipoprotein(a): biology and clinical importance. Clin Biochem Rev. 2004;25(1):69–80.
   PubMedGoogle Scholar
• Kostner KM, Marz W, Kostner GM. When should we measure lipoprotein (a)? Eur Heart J. 2013;34(42):3268–3276. doi:10.1093/eurheartj/eht053
   PubMed Web of Science ®Google Scholar
• Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):157–164. doi:10.1097/MED.0000000000000237
   PubMed Web of Science ®Google Scholar
• Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991;113(6):1439–1445. doi:10.1083/jcb.113.6.1439
   PubMed Web of Science ®Google Scholar
• Manocha A, Srivastava LM. Lipoprotein (a): a unique independent risk factor for coronary artery disease. Indian J Clin Biochem. 2016;31(1):13–20. doi:10.1007/s12291-015-0483-3
   PubMedGoogle Scholar
• Malaguarnera M, Vacante M, Russo C, et al. Lipoprotein(a) in cardiovascular diseases. Biomed Res Int. 2012;2013:650989.
   PubMed Web of Science ®Google Scholar
• Barre DE. Lipoprotein (a) reduces platelet aggregation apo(a)-mediated decreases in production via thromboxane A 2. Platelets. 1998;9(2):93–96. doi:10.1080/09537109876852
   PubMed Web of Science ®Google Scholar
• Barre D. Apolipoprotein (a) mediates the lipoprotein (a)-induced biphasic shift in human platelet cyclic AMP. Thromb Res. 2003;112(5–6):321–324. doi:10.1016/j.thromres.2004.01.002
   PubMed Web of Science ®Google Scholar
• Barre DE. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor. Thromb Res. 2007;119(5):601–607. doi:10.1016/j.thromres.2006.04.013
   PubMed Web of Science ®Google Scholar
• Tsironis L, Mitsios J, Milionis H, Elisaf M, Tselepis A. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res. 2004;63(1):130–138. doi:10.1016/j.cardiores.2004.03.005
   PubMed Web of Science ®Google Scholar
• Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998;18(9):1393–1399. doi:10.1161/01.ATV.18.9.1393
   PubMed Web of Science ®Google Scholar
• Martínez C, Rivera J, Loyau S, et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost. 2001;85(4):686–693. doi:10.1055/s-0037-1615654
   PubMed Web of Science ®Google Scholar
• Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5):745–757. doi:10.1194/jlr.R060582
   PubMed Web of Science ®Google Scholar
• Donataccio MP, Puymirat E, Vassanelli C, et al. Presentation and revascularization patterns of patients admitted for acute coronary syndromes in france between 2004 and 2008 (from the national observational study of diagnostic and interventional cardiac catheterization [ONACI]). Am J Cardiol. 2014;113(2):243–248. doi:10.1016/j.amjcard.2013.09.014
   PubMed Web of Science ®Google Scholar
• Fox KAA, Eagle KA, Gore JM, Steg PG, Anderson FA. The global registry of acute coronary events, 1999 to 2009-GRACE. Heart. 2010;96(14):1095–1101. doi:10.1136/hrt.2009.190827
   PubMed Web of Science ®Google Scholar
• Peng Y, Shao Z, Jiang J, et al. Association between serum lipoprotein (a) levels and major adverse cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction. Int J Clin Exp Med. 2017;10(1):897–904.
   Web of Science ®Google Scholar
• Mitsuda T, Uemura Y, Ishii H, et al. Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. Heart Vessels. 2016;31(12):1923–1929. doi:10.1007/s00380-016-0823-0
   PubMed Web of Science ®Google Scholar
• Cho JY, Jeong MH, Ahn Y, et al. High lipoprotein(a) levels are associated with long-term adverse outcomes in acute myocardial infarction patients in high killip classes. Korean Circ J. 2010;40(10):491–498. doi:10.4070/kcj.2010.40.10.491.
   PubMedGoogle Scholar
• Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76–84. doi:10.5935/abc.20140101
   PubMed Web of Science ®Google Scholar
• Ikenaga H, Ishihara M, Inoue I, et al. Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ J. 2011;75(12):2847–2852. doi:10.1253/circj.CJ-11-0365
   PubMed Web of Science ®Google Scholar
• Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the biomarCaRE consortium. Eur Heart J. 2017;38(32):2490–2498. doi:10.1093/eurheartj/ehx166
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Circ. 2000;102(10):1082–1085. doi:10.1161/01.CIR.102.10.1082
   PubMed Web of Science ®Google Scholar
• Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44(11):2301–2306. doi:10.1093/clinchem/44.11.2301
   PubMed Web of Science ®Google Scholar
• Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, Maerz W. Lipoprotein (a) and risk of cardiovascular disease–a systematic review and meta analysis of prospective studies. Clin Lab. 2011;57(3–4):143–156.
   PubMed Web of Science ®Google Scholar
• Lan Y, Zhao X, Wang X, et al. Lipoprotein(a) as a risk factor for predicting coronary artery disease events: a meta-analysis. Biomark J. 2018;4(3):17.
   Google Scholar
• Wang Z, Zhai X, Xue M, Cheng W, Hu H. Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis. Lipids Health Dis. 2019;18(1):150. doi:10.1186/s12944-019-1092-6
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, Danesh J. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412.
   PubMed Web of Science ®Google Scholar
• Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496–503. doi:10.1016/j.atherosclerosis.2015.08.021
   PubMed Web of Science ®Google Scholar
• Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke. Stroke. 2007;38(6):1959–1966. doi:10.1161/STROKEAHA.106.480657
   PubMed Web of Science ®Google Scholar
• Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a). J Am Coll Cardiol. 2014;64(9):851–860. doi:10.1016/j.jacc.2014.03.061
   PubMed Web of Science ®Google Scholar
• Kamiński KA, Tycińska AM, Stepek T, et al. Natural history and risk factors of long-term mortality in acute coronary syndrome patients with cardiogenic shock. Adv Med Sci. 2014;59(2):156–160. doi:10.1016/j.advms.2013.12.003
   PubMed Web of Science ®Google Scholar
• Kaulgud RS, Vijayalxmi PB, Arun BS, Supriya RR, Vigneshwar M. Novel biomarkers for risk stratification of acute coronary syndromes. Int J Biomed Res. 2015;6(8):539. doi:10.7439/ijbr.v6i8.2346
   Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. doi:10.1093/eurheartj/ehq386.
   PubMed Web of Science ®Google Scholar